U.S. Markets closed

Novartis AG (NVS)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
86.340.00 (0.00%)
At close: 4:02PM EDT
People also watch
GSKSNYAZNLLYABT
Full screen
Previous Close86.34
Open85.57
Bid0.00 x
Ask0.00 x
Day's Range85.51 - 86.57
52 Week Range66.93 - 86.90
Volume2,199,472
Avg. Volume2,267,079
Market Cap196.6B
Beta0.72
PE Ratio (TTM)32.46
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.72 (3.29%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Better Buy: Exelixis, Inc. vs. Novartis AG
    Motley Fool19 hours ago

    Better Buy: Exelixis, Inc. vs. Novartis AG

    Is fast-rising Exelixis a better stock pick than huge drugmaker Novartis?

  • Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod
    Zacks2 days ago

    Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

    All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

  • Reuters2 days ago

    Novartis breast cancer drug Kisqali wins European panel backing

    A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer. The EMA's Committee for Medicinal Products for Human Use (CHMP) backed Kisqali in combination with hormone therapy as a first-line treatment for hormone receptor positive, human epidermal growth factor receptor-2 negative locally advanced or metastatic breast cancer. This latest CHMP opinion sets the stage for likely European Commission approval this year.